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Available online 4 October 2016Functional MRI studies have helped to elucidate underlying mechanisms in complex neurological and neuropsy-
chiatric disorders. Disease processes often involve complex large-scale network interactions, extending beyond
the presumed main disease focus. Given both the complexity of the clinical phenotype and the underlying dys-
functional brain circuits, so called pharmaco-fMRI (ph-MRI) studies probe pharmacological effects on functional
neuro-anatomy, and can help to determine early treatment response, mechanisms of drug efﬁcacy and side ef-
fects, and potentially advance CNS drug development. In this review, we discuss recent ph-MRI research in
threemajor neuropsychiatric and neurological disorders and associatednetwork alterations, namely selective se-
rotonin and noradrenergic reuptake inhibitors in affective disorders and emotional processing circuits; antiepi-
leptic drugs in epilepsy and cognitive networks; and stimulants in attention-deﬁcit/hyperactivity disorder and
networks of attention control. We conclude that ph-MRI studies show consistent and reproducible changes on
disease relevant networks, and prove sensitive to early pharmacological effects on functional anatomy associated
with disease. Further CNS drug research and development would beneﬁt greatly from improved disease pheno-
typing, or biomarkers, using advanced imaging techniques.
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In functional MRI (fMRI), reproducible patterns of activation or de-
activation elicited bymotor, cognitive or other tasks could be identiﬁed,
such as the defaultmode network, a set of brain regions, which are com-
monly deactivated during goal-directed tasks (Bullmore, 2012; Raichle
et al., 2001). This enables to explore disease effects on regional and net-
work functional anatomy, and vice versa, may help to establish consis-
tent (functional) imaging phenotypes of CNS diseases. These are
particularly in demand given the somewhat dissatisfying trial-and-
error approach when it comes to medication choices, without being
able to tailor drugs a priori to the individual patient's disease phenotype.
Indeed, what we have learned from fMRI studies in these disorders so
far is that disease processes often involve complex large-scale network
interactions, extending beyond the presumedmain disease focus. Imag-
ing phenotypes may therefore provide surrogate markers to, ﬁrstly, in-
vestigate drug effects at a network level in so called pharmaco-fMRI
(ph-MRI) studies and, secondly, to early establish treatment efﬁcacy,
dose-response relationships and cognitive side-effects of CNS drugs
(Nathan et al., 2014).
2. Pharmaco-fMRI: concept and challenges
Ph-MRI is a promising emerging application to assess regional net-
work effects of and treatment response to speciﬁc medications. Several
methodological difﬁculties have to be considered:
FMRI indirectly probes neuronal activity bymeasuring the BloodOx-
ygenation Level Dependent (BOLD) activity, which results from changes
in levels of deoxyhaemoglobin in response to local metabolic demands
of neuronal function (Logothetis, 2008).
The signal change in fMRI related to a drug is low; hence drug effects
are generally studied as an interaction effect in task-related fMRI, i.e.
task-related activation patterns for a drug are compared to those with-
out the drug or placebo. Drugs can inﬂuence the BOLD signal both at a
neuronal and vascular level complicating the interpretation of the ef-
fects observed. Approaches to quantify those effects on BOLD contrast
include measurements of physiological changes in brain perfusion
with blood ﬂow measurements with arterial spin labelling (Borsook et
al., 2013). As the BOLD signal is contaminated by low-frequency noise,
detection of slowly evolving medication effects can be challenging
(Mehta and O'Daly, 2011).
Ph-MRI has the major advantage that it can investigate effects of
pharmacological agents at a network level and remotely from regions
of highest target receptor densities, whereas PET andmolecular studies
can deﬁne target receptor occupancy and afﬁnity without necessarily
translating effects to large-scale networks (Mehta and O'Daly, 2011).
Hence ph-MRI enables a “system evaluation” of networks underlying
behavioural effects of a drug, independent of its biochemical mecha-
nism of action. CNS drugs often target several receptor sub-types with
varying regional distribution, and drug efﬁcacy may differ across these
targets. Functional MRI can monitor the combined effect of these inter-
actions across multiple brain regions (Borsook et al., 2006); hence ph-
MRI has the potential to provide “mechanism-related activation maps”
(Nathan et al., 2014) to serve as targets for testing of drug effects. A fur-
ther advantage is that fMRI does not use ionizing radiation and has no
known biological side effects.
3. Pharmaco fMRI: functional networks and speciﬁc medication
effects
In the following, the effect of CNS drugs onmajor neuronal networks
will be discussed exemplary in neuropsychiatric conditions. It is impor-
tant to note that regional medication effects have usually been probed
in the context of cognitive or emotional paradigms, similar to those par-
adigms employed to explore disease-related functional alterations at a
regional and network level. Hence, activation changes attributed tomedication effects have to be considered in the context of possible addi-
tional effects of disease load or activity, and the sensitivity of the task to
unveil disease and medication related changes on functional anatomy.
3.1. SSRI, NaRI and emotional processing circuits
Most ph-MRI studies in affective disorders explore the effects of se-
lective serotonin (SSRI) or noradrenergic (NaRI) reuptake inhibitors and
benzodiazepines. Overall, fMRI studies in major depression, and studies
employing anxiety provocation in patients with anxiety disorders re-
port attenuation of the limbic and para-limbic regions, and enhanced
activation within prefrontal networks following SSRI/NaRI treatment
relative to the drug naïve state (Delaveau et al., 2011; Furmark et al.,
2002; Phan et al., 2013). In healthy controls, SSRI treatment lead to at-
tenuation of amygdala activation during a negative emotional stimuli
task (Anderson et al., 2007; Harmer et al., 2006; Windischberger et al.,
2010). This has been similarly reported after single dose application of
anxiolytic benzodiazepines (Paulus et al., 2005). On the contrary, in-
creased amygdala activation was observed with a short SSRI trial in
healthy subjects during a positive emotional paradigm, suggesting
that antidepressants may modulate abnormal emotional processing in
the diseased (Norbury et al., 2009). In a behavioural study of depressed
patients, changes in emotional processing within the ﬁrst two weeks of
SSRI/NaRI treatmentwere predictive of later treatment response, before
therapeutic effects were observed (Tranter et al., 2009). Pre-treatment
activationwithin limbic and fronto-cortical regionswas found to bepre-
dictive of treatment success with SSRI/NaRI in anxious patients
(McClure et al., 2007; Nitschke et al., 2009).
Normalization of limbic and fronto-cortical imbalance has also been
observed following non-pharmacological treatment, such as cognitive
behavioural therapy (Fu et al., 2008; Furmark et al., 2002) and neuro-
modulation (Mayberg et al., 2005), suggesting that observed effects
could represent a common treatment pathway; the speciﬁcity of antide-
pressant medication on the fronto-limbic network therefore remains
unclear.
In resting-state functional connectivity studies in major depressive
disorder, treatment response to SSRI/NaRI was associated with in-
creased connectivity between cortico-frontal and limbic regions, likely
resulting in greater control over emotion regulation (Dichter et al.,
2015). A meta-analysis of fMRI studies in patients with major depres-
sion employing emotional stimuli provocation also reports enhanced
deactivation of areas of the default mode, including anterior and poste-
rior cingulate cortices, precuneus and the inferior parietal lobule
(Delaveau et al., 2011). There is some evidence that antidepressant
treatment may normalize hyper-connectivity within the default mode
network, though without evidence of a clear correlation with clinical
improvement (Gudayol-Ferré et al., 2015).
3.2. Antiepileptic drugs and higher cognitive networks
Given the variety of available anticonvulsive drugs (AED) and the
heterogeneity of epilepsy syndromes in terms of networks involved,
fMRI surrogate markers for early determination of treatment efﬁcacy
and likelihood of side effects are urgently needed. So far, ph-MRI studies
are rare and usually of small sample sizes (Koepp, 2011). Ph-fMRI stud-
ies in epilepsy are hampered by the fact that patients usually are already
on AED, therefore the study design has to control for effects of co-
medication in addition to other confounders, such as disease activity
or disease severity and comorbidities (Beltramini et al., 2015). Most
ph-MRI studies in epilepsy patients employ cognitive tasks, likely be-
cause cognitive network alterations in epilepsy are well known, and
cognitive side effects are a major factor for medication adherence
(Bootsma et al., 2009; Fisher et al., 2000). AED appear to lead to attenu-
ation of either task-related activation and/or deactivation in co-localised
hubs critical to both the speciﬁc epilepsy syndrome and the network
relevant to the cognitive function studied.
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The ﬁrst ph-fMRI study in epilepsy employed a visual-spatial mem-
ory retrieval task in patients with refractory temporal lobe epilepsy
(TLE) (Jokeit et al., 2001) evaluating the relationship of mesio-temporal
fMRI activation and carbamazepine serum (CBZ) concentrations. The
extent of task and syndrome speciﬁc fMRI activation within the medial
temporal lobewas negatively correlated with the CBZ serum levels. The
effect was most marked with close to toxic drug levels. However, there
was no psychometric data available to relate effects tomemory function
in these patients.
Employing a graph theoretical approach and resting state fMRI in a
TLE cohort treated with CBZ or oxcarbazepine (OXC) and comparing
to thosewhowere on other AED (Haneef et al., 2015), altered “hubness”
was reported in those on CBZ/OXC, i.e. less highly connected nodes
connecting distant parts of the brain. Whereas betweenness centrality,
or hubness, was reduced within the limbic circuit and thalamus with
CBZ/OXC use, it was increased in default mode regions, i.e. cingulate
and posterior cingulate/precuneus.
Previous data in TLE suggests a “re-distribution” of hub regions with
high betweenness centrality to mainly paralimbic and temporal associ-
ation cortices (Bernhardt et al., 2011), hence suggesting a region-specif-
ic effect of CBZ/OXC on disease-related network changes.
3.2.2. Valproate
In a placebo-controlled, combined transcranialmagnetic stimulation
(TMS) and fMRI study, valproate (VPA) and lamotrigine (LTG) demon-
strated network speciﬁc effects. When TMS was applied over the
motor region, both agents reduced TMS-speciﬁc effective connectivity
between the primary motor and pre-motor cortex and the primary
motor and supplementary motor area (SMA). Only LTG-treatment was
associatedwith increased effective connectivity between the left dorso-
lateral prefrontal cortex and anterior cingulate when TMS was applied
over the prefrontal cortex (Li et al., 2011).
For VPA, similar effects are seen in juvenile myoclonic epilepsy
(JME). This syndrome has been associated with increased functional
and structural connectivity between central motor and prefrontal cog-
nitive networks, likely accounting for cognitively triggered jerks, a re-
ﬂex trait highly associated with the syndrome (Vollmar et al., 2011,
2012; Yacubian and Wolf, 2014). Abnormal motor cortex co-activation
with cognitive networks during an fMRI working memory task in JME
was shown to be modulated by disease factors, i.e. the trait was en-
hancedwithmore frequent seizures and during themorning, when sei-
zures occur more frequently due to the typical chrono-dependency of
the syndrome. Vice versa, abnormal co-activation was attenuated with
increasing VPA dose, consistent with the clinical impression that VPA
is effective in JME, particularly in treatment of myoclonic jerks, and
not necessarily associated with cognitive side effects (Wandschneider
et al., 2012).
3.2.3. Levetiracetam
Several studies attribute a favourable cognitive proﬁle to Levetirace-
tam (LEV) (Helmstaedter and Witt, 2008), considered to be superior to
CBZ (Helmstaedter and Witt, 2010).
Consistent with neurobehavioural data, fMRI studies show a beneﬁ-
cial effect of LEV to cognitive networks. Task- and syndrome speciﬁc re-
gional fMRI effects, aswell as dose-dependencywere demonstrated in a
verbal and visual-spatial working memory task in left and right TLE pa-
tients, comparing those treated with to those without LEV: Patients on
LEV showed an augmentation of task-related deactivation in the dis-
eased temporal lobe compared to patientswithout LEV;more speciﬁcal-
ly, this effect was seen in the left mid-temporal gyrus in left TLE during
the verbal, and the right hippocampus in right TLE during the visual-
spatial task and becamemore apparent with increasing LEV dose. As pa-
tients on LEV showed similar task-related deactivation patterns to
healthy controls, LEV appears to be associated with restoration of nor-
mal fMRI activation (Fig. 1). (Wandschneider et al., 2014).Though out-of-scanner neurobehavioural data, including frontal
lobe cognitive measures, did not differ between those treated with
LEV and those without, LEV modulated fMRI deactivation patterns can
be interpreted as a beneﬁcial drug effect. This is corroborated by data
in healthy subjects and epilepsy patients where progressive deactiva-
tion of mesial temporal structures during cognitive tasks is observed
with improved performance (Cousijn et al., 2012; Stretton et al., 2013).
Functional MRI data from individuals with amnestic mild cognitive
impairment,which is associatedwith a risk of Alzheimer's disease, dem-
onstrated that dysfunctional, increased hippocampal activation in the
dentate gyrus/CA3was normalized by low-dose LEV treatmentwith im-
provement of memory performance (Bakker et al., 2012, 2015). Hence
across different disease entities, LEV appears to have a localisation-
speciﬁc effect, which is both relevant to seizure generation and propa-
gation, and cognitive performance via a major hub of the default mode
network.
3.2.4. Topiramate and zonisamide
For TPM, cognitive dysfunction has been described in patients with
epilepsy, migraine and healthy controls, characterised by reduced at-
tention, psychomotor speed, short-termmemory and more speciﬁcally,
impairment of expressive language andworkingmemory. These deﬁcits
are noted even after single-dose administration and on steady-dose in
mono- or combination therapy, irrespective of seizure control. Psycho-
metric measures consistently improve after signiﬁcant dose reduction
or discontinuation. (Bootsma et al., 2008; Martin et al., 1999; Meador
et al., 2005;Mula and Trimble, 2009; Thompson et al., 2000) Zonisamide
treatment leads to similar, probably less pronounced neurocognitive
impairment (Mula and Trimble, 2009; Ojemann et al., 2001).
Topiramate is the AEDmost studied in ph-MRI trials, though in rela-
tively small cohorts. Five fMRI studies employed expressive language
tasks in two healthy subjects, ﬁve to 16 epilepsy and ten migraine pa-
tients after a single dose or on steady-state TPM treatment. Combined
results convey a pattern of reduced activation in language relevant re-
gions, i.e. dominant inferior and middle frontal gyri, superior temporal
gyrus (De Ciantis et al., 2008; Jansen et al., 2006; Szaﬂarski and
Allendorfer, 2012), and a failure to deactivate task-negative regions, in-
cluding the default mode network (Szaﬂarski and Allendorfer, 2012;
Tang et al., 2016; Yasuda et al., 2013). Successful task execution in gen-
eral has been associated with effective deactivation of task-negative
areas (Raichle et al., 2001; Seghier and Price, 2012).
Both AED contain a sulfa moiety and speciﬁc detrimental effects on
verbal intellectual abilities have also been described in a related drug,
sulthiame (Dodrill, 1975). Sulfa-compound containing drugs share the
carbonic anhydrase inhibitionmechanism and themechanism underly-
ing the similar fMRI changes in TPM and ZNS may be comparable to ac-
etazolamide, another carbonic anhydrase inhibitor, which has been
shown to increase blood ﬂowwith constant oxygen consumption, lead-
ing to an enhancement of the resting BOLD and decrease of the activa-
tion BOLD (Bruhn et al., 1994).
3.3. Stimulants and networks involved in attention control
Attention-deﬁcit/hyperactivity disorder is characterised by inatten-
tion, impulsiveness and hyperactivity, and in behavioural studies, asso-
ciated with deﬁcits in task inhibition, attention, working memory and
timing. Probing the underlying regional functional anatomy, main
tasks employed in fMRI studies of ADHD are Stop or Go/No-Go tasks,
measuring the ability to suppress an already triggered motor response;
time discrimination tasks, duringwhich the subject has to decide which
of displayed items stays on the screen for the longer time; and n-back
working memory tasks. (Rubia et al., 2014) Abnormal regional activa-
tion patterns during these tasks have been reported in the fronto-
parietal cognitive and attentional networks, the default mode, striatal
and limbic regions (Cortese et al., 2012; Rubia, 2011).
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answers, Liddle et al. (2011) demonstrated that motivation can modu-
late effects of methylphenidate, a dopamine reuptake inhibitor, via the
default mode network in ADHD. Task induced deactivations were ob-
served in the healthy control cohort independently from the level of in-
centives. In patients, methylphenidate and high incentive had similar
effects on activation patterns and performance: Patients onmethylphe-
nidate did not differ from controls, irrespective of incentive levels, i.e.
medication normalized their raised motivational threshold. When off
medication and at low incentive, there was attenuated deactivation
within the default mode network in ADHD, which normalized with in-
creased incentive. This data suggests that the default mode network is
modulated by dopamine, even though it does not include regions with
high density dopaminergic projections, such as the striatum (Mehta,
2011). As corroborated by healthy control data from a combined [-
11C]cocaine PET and fMRI study employing an attentional paradigm, in-
creased DAT availability in the striatum, resulting in lower dopamine
levels at the synapse, was associated with attenuated deactivation of
the precuneus, and increased DAT in the caudate was associated with
less deactivation of the precuneus with increasing attentional load;
vice versa lower DAT availability as in ADHD patients on methylpheni-
date likely modulates deactivation in the default mode network facili-
tating attention (Tomasi et al., 2009). Indeed, a rewarded working
memory fMRI study in healthy controls contrasting the effects of meth-
ylphenidate and the noradrenaline reuptake inhibitor atomoxetine
demonstrated that both drug effects were context-dependent and
showed an interaction with the degree of incentive: In the reward con-
text, both drugs lead to attenuation of working memory networks and
enhanced task-dependent deactivation in the default mode network
in comparison to placebo. By contrast, during non-rewarded trials,
only methylphenidate lead to increased activity in workingmemory re-
gions and attenuated default mode deactivation compared to placebo,
which were similar activation patterns when contrasting reward to
non-reward (Marquand et al., 2011). Thus, dynamic interactions be-
tween motivational state and drug effects have to be considered in
ph-MRI studies.
4. The use of ph-MRI in CNS drug development
This topic has recently received expert reviews (Borsook et al., 2006,
2013; Nathan et al., 2014).
Challenges for CNS drug research include the complexity of neuronal
networks, and misclassiﬁcation, or incorrect phenotyping of patients,
particularly in psychiatric conditions. In addition, outcome measures
often rely on subjective ratings, and even if there are objective clinical
measures, such as seizure frequency, their quantiﬁcation is dependent
on the patient's or relatives' accounts and often unreliable (Cook et al.,
2013). Ph-MRI hence poses a unique opportunity for CNS drug research
tomeasure drug effects on a functional network level in the living brain,
both in healthy and diseased.
During Phase 1 drug trials to evaluate drug safety, dose range and
side effects in a small group of people, ph-MRI could help to determine
potential side effects by capturing e.g. effects on cognitive networks, and
dose ranges by e.g. exploring minimal doses that lead to signiﬁcant
changes in neuronal circuits (Borsook et al., 2013). In combinationFig. 1. (Wandschneider et al., 2014). Group comparisons between patients with and without L
areas of task-related deactivation networks in controls and all patients during the left- and r
show similar patterns of deactivation, patients without LEV show less deactivation in the med
(Fig. A). During the verbal WM task, left TLE patients without LEV signiﬁcantly fail to deactiva
20 voxels threshold extent). During the right-lateralising visual-spatial task, patients with righ
TLE without LEV N right TLE with LEV, p b 0.001, 20 voxels threshold extent). A post-hoc a
temporal lobe deactivation through LEV. The lower the LEV dose, the lesser the right hippo
threshold extent). A similar dose effect is observed in left TLE patients during the verbal W
hippocampus becomes less strongly deactivated with lower LEV dose. CTR = healthy control
epilepsy; WM=working memory.with a ligand-based approach, such as PET, dosing ranges can be reﬁned
by determining how much receptor occupancy (PET) will produce the
desired functional network effects in ph-MRI (Borsook et al., 2013).
Whole-brain information on functional drug effects early on in CNS tri-
als can also help to tailor subsequent and larger-scale trials accordingly.
When evaluating new agents in patient populations, from Phase 2 trials
onwards, using effects on functional networks in ph-MRI as endpoint
measures has the potential to produce more consistent and objective
data with less variance than e.g. subjective ratings on efﬁcacy and side
effects, and therefore could reduce required sample sizes considerably.
This would be even more efﬁcient, if imaging is used to better deﬁne
the diseased population a priori by characterizing certain imaging bio-
markers of disease; drug effects on these with direct gain of insight
into their underlying mechanisms, as well as effective drug response
could then be studied by ph-MRI (Engel, 2011; Wiedemann, 2011).
Such biomarkers could be used for proof-of-concept studies to early
identify promising novel compounds (Nathan et al., 2014), even in the
absence of initial symptom relief as one commonly observes e.g. in an-
tidepressant treatment. Clinical trials can be hampered by natural ﬂuc-
tuations in disease severity, leading to a falsely perceived beneﬁt or
failure of a substance. Ph-MRI can therefore help to disentangle disease
states and drug effects.
Beyond trials for potentially new CNS drugs, longitudinal imaging
studies can capture long-term drug effects on brain circuits, in order
to understand whether chronic drug exposure can eventually lead to
normalization of brain function, and mechanisms in non-responders,
as well as the evolution of treatment resistance to a substance that pre-
viously lead to long-term symptom beneﬁt, as e.g. observed in epilepsy.5. Conclusion
Pharmaco-fMRI studies, show consistent and reproducible changes
on disease relevant networks and prove sufﬁciently sensitive to detect
dose-dependent network changes early, prior to clinical change, and
can predict long-term efﬁcacy, providing exciting new tools for novel
CNS drug research.
It remains uncertain, how speciﬁc these effects are for single com-
pounds: observed effects on abnormal functional anatomy are likely to
represent common pathways for several drug classes or even non-phar-
macological treatment, such as SSRI, NaRI, benzodiazepines and cogni-
tive-behaviour therapy in affective disorders.
Overall inferences on speciﬁc drugs and diseases are difﬁcult, as
studies employed a variety of tasks. Observed effects on task-related de-
activations or the default mode network appear to be more robust and
reproducible than task-active functional anatomy. Furthermore, drug
efﬁcacy is probably best studied via functional connectivity analysis,
whereas task-based regional activation may be more appropriate for
evaluation of speciﬁc cognitive side effects.
Pharmaco-fMRI studies have been used primarily in treatment re-
search of psychiatric diseases and pain studies. For these entities, treat-
ment research is reliant on subjectivemeasures and in need of objective
endpoints. Ph-MRI studies have the potential to improve treatment de-
cisions for complex neurological conditions, such as epilepsy, where
choice of treatment is done mainly in a trial-and-error fashion.evetiracetam (LEV) during two working memory (WM) fMRI paradigms. Group maps of
ight-lateralising task, are demonstrated. Whereas healthy controls and patients on LEV
ial temporal lobe areas than both controls and patients on LEV in either lateralising task
te the left mid-temporal gyrus (Fig. B; left TLE without LEV N left TLE with LEV, p b 0.001,
t TLE who are not treated with LEV fail to deactivate the right hippocampus (Fig. B; right
nalysis in patients treated with LEV demonstrated a dose-dependent effect of mesial
campus is deactivated during the visual-spatial WM task (Fig. C; p b 0.001, 20 voxels
M task at a lower level of signiﬁcance (Fig. C; p b 0.05, uncorrected): The left N right
s; LEV = levetiracetam; LTLE = left temporal lobe epilepsy; RTLE = right temporal lobe
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